{"id":2519,"date":"2025-11-26T08:02:31","date_gmt":"2025-11-26T01:02:31","guid":{"rendered":"https:\/\/naviva.com.vn\/?p=2519"},"modified":"2025-12-25T16:28:53","modified_gmt":"2025-12-25T09:28:53","slug":"barycela-a-new-generation-varicella-vaccine-from-gc-biopharma","status":"publish","type":"post","link":"https:\/\/naviva.com.vn\/en\/barycela-a-new-generation-varicella-vaccine-from-gc-biopharma","title":{"rendered":"BARYCELA \u2013 A New-Generation Varicella Vaccine from GC Biopharma"},"content":{"rendered":"<p><span style=\"font-size: 14pt; color: #000000; font-family: 'times new roman', times, serif;\"><b>BARYCELA inj.<\/b><span style=\"font-weight: 400;\"> is a varicella vaccine manufactured by GC Biopharma (South Korea). With more than 30 years of experience and a presence in over 30 countries, GC Biopharma is recognized as one of Asia\u2019s leading and most reputable vaccine manufacturers.<\/span><\/span><\/p>\n<h2><span style=\"font-size: 14pt; color: #000000; font-family: 'times new roman', times, serif;\"><b>1. A 30-Year Journey in Varicella Vaccine Development by GC Biopharma<\/b><\/span><\/h2>\n<p><span style=\"font-weight: 400; font-size: 14pt; color: #000000; font-family: 'times new roman', times, serif;\">GC Biopharma is a pioneer in South Korea in the research and production of varicella vaccines.<\/span><\/p>\n<p><span style=\"font-weight: 400; font-size: 14pt; color: #000000; font-family: 'times new roman', times, serif;\">First-generation varicella vaccine (Varicella \u2013 MAV\/06 strain):<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-size: 14pt; color: #000000; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Licensed in South Korea since 1993<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-size: 14pt; color: #000000; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Incorporated into the National Expanded Program on Immunization (EPI) in 2005<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-size: 14pt; color: #000000; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">More than 30 million doses administered, generating robust safety data<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<\/ul>\n<h2><span style=\"font-size: 14pt; color: #000000; font-family: 'times new roman', times, serif;\"><b>2. BARYCELA \u2013 Second-Generation MAV\/06 Strain Varicella Vaccine with Enhanced Manufacturing Processes<\/b><\/span><\/h2>\n<p><span style=\"font-weight: 400; font-size: 14pt; color: #000000; font-family: 'times new roman', times, serif;\">BARYCELA was developed based on the first-generation platform, incorporating key advancements:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-size: 14pt; color: #000000; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Manufactured using an enhanced process that meets international standards<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-size: 14pt; color: #000000; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Utilizes the WHO-recommended MRC-5 cell line<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-size: 14pt; color: #000000; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Antibiotic-free, in compliance with FDA standards \u2013 Aseptic Processing<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400; font-size: 14pt; color: #000000; font-family: 'times new roman', times, serif;\">As of March 2025, GC Biopharma has:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-size: 14pt; color: #000000; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Supplied 2 million doses of BARYCELA to the international market<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-size: 14pt; color: #000000; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Supplied 2.5 million doses to Brazil\u2019s National Expanded Program on Immunization through PAHO<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<\/ul>\n<p><span style=\"font-size: 14pt; color: #000000; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">BARYCELA has been licensed in:<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><span style=\"font-weight: 400;\"> Pakistan (2022), Turkey (2024), Egypt, Libya, and Brazil (2025), and is currently undergoing registration in multiple other countries.<\/span><\/span><\/p>\n<p><a href=\"https:\/\/naviva.com.vn\/wp-content\/uploads\/2025\/11\/vac-xin-thuy-dau-barycela-4.png\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-2427\" src=\"https:\/\/naviva.com.vn\/wp-content\/uploads\/2025\/11\/vac-xin-thuy-dau-barycela-4.png\" alt=\"\" width=\"3924\" height=\"2900\" srcset=\"https:\/\/naviva.com.vn\/wp-content\/uploads\/2025\/11\/vac-xin-thuy-dau-barycela-4.png 3924w, https:\/\/naviva.com.vn\/wp-content\/uploads\/2025\/11\/vac-xin-thuy-dau-barycela-4-300x222.png 300w, https:\/\/naviva.com.vn\/wp-content\/uploads\/2025\/11\/vac-xin-thuy-dau-barycela-4-648x479.png 648w, https:\/\/naviva.com.vn\/wp-content\/uploads\/2025\/11\/vac-xin-thuy-dau-barycela-4-768x568.png 768w, https:\/\/naviva.com.vn\/wp-content\/uploads\/2025\/11\/vac-xin-thuy-dau-barycela-4-1600x1182.png 1600w, https:\/\/naviva.com.vn\/wp-content\/uploads\/2025\/11\/vac-xin-thuy-dau-barycela-4-160x118.png 160w\" sizes=\"auto, (max-width: 3924px) 100vw, 3924px\" \/><\/a><\/p>\n<p style=\"text-align: center;\"><span style=\"color: #000000; font-family: 'times new roman', times, serif;\">Image: BARYCELA \u2013 A Korean varicella vaccine free from antibiotics<\/span><\/p>\n<h2><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><b>3. Quality Standards in Accordance with the World Health Organization (WHO)<\/b><\/span><\/h2>\n<p><span style=\"font-weight: 400; color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">BARYCELA fully meets WHO standards for quality, safety, and efficacy, including:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">WHO Prequalification (WHO-PQ)<\/span><b><br \/>\n<\/b><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Comprehensive inspection and evaluation under CGMP \u2013 Aseptic Processing standards<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<\/ul>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><b>Reference documents:<\/b><\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><a style=\"color: #000000;\" href=\"https:\/\/extranet.who.int\/prequal\/vaccines\/p\/barycela-inj\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">https:\/\/extranet.who.int\/prequal\/vaccines\/p\/barycela-inj<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/a><a style=\"color: #000000;\" href=\"https:\/\/extranet.who.int\/prequal\/sites\/default\/files\/vwa_vaccine\/pq_381_Varicella__GC_VPASR-WHOPAR-2023.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">https:\/\/extranet.who.int\/prequal\/sites\/default\/files\/vwa_vaccine\/pq_381_Varicella__GC_VPASR-WHOPAR-2023.pdf<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/a><\/span><\/p>\n<h2><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><b>4. Regulatory Dossier and Clinical Data in Vietnam<\/b><\/span><\/h2>\n<p><span style=\"font-weight: 400; color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">In accordance with regulations of the Ministry of Health of Vietnam, BARYCELA has:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Had its prescribing information approved by the Drug Administration of Vietnam<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Completed a clinical study evaluating safety and immunogenicity (August 8, 2024)<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Received marketing authorization on July 7, 2025<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Been granted batch release certification on November 5, 2025 by the National Institute for Control of Vaccines and Biologicals<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<\/ul>\n<h2><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><b>5. Key Advantages in Immunization Practice<\/b><\/span><\/h2>\n<h3><span style=\"font-weight: 400; color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">a. Proven immunogenicity and safety<\/span><\/h3>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Controlled clinical studies demonstrate that BARYCELA has comparable immunogenicity and safety to the reference vaccine:<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><a style=\"color: #000000;\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0264410X21001614\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0264410X21001614<\/span><\/a><\/span><\/p>\n<p><span style=\"color: #000000; font-family: 'times new roman', times, serif; font-size: 14pt;\">b. Antibiotic-free formulation<\/span><\/p>\n<p><span style=\"font-weight: 400; color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">A distinguishing feature compared to most currently available varicella vaccines.<\/span><\/p>\n<p><span style=\"font-weight: 400; color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Manufactured in accordance with FDA Aseptic Processing standards.<\/span><\/p>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><a style=\"color: #000000;\" href=\"https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice<\/span><\/a><\/span><\/p>\n<h3><span style=\"font-weight: 400; color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">c. 2.4-fold higher stability<\/span><\/h3>\n<p><span style=\"font-weight: 400; color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Thanks to improved manufacturing processes, the minimum viral potency is maintained at \u2265 3,800 PFU, ensuring vaccine stability throughout its product lifecycle.<\/span><\/p>\n<h3><span style=\"font-weight: 400; color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">d. Cost-effective pricing to support expanded immunization coverage<\/span><\/h3>\n<p><span style=\"font-weight: 400; color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">BARYCELA is competitively priced, enabling vaccination providers to more easily expand services across diverse population groups. Affordable pricing encourages earlier vaccination in children, thereby increasing vaccine coverage, reducing outbreak risk, and lowering treatment burdens within the community.<\/span><\/p>\n<h2><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><b>6. Disease Burden and Complications of Varicella<\/b><\/span><\/h2>\n<p><span style=\"font-weight: 400; color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">According to data from the CDC and WHO, varicella is often mild but may cause serious complications even in otherwise healthy children, particularly in school settings.<\/span><\/p>\n<p><span style=\"font-weight: 400; color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">Reported complications include:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Skin and soft tissue infections (impetigo, cellulitis, abscesses)<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Acute cerebellitis, resulting in tremors and ataxia<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Encephalitis and meningitis<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Varicella pneumonia<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Permanent scarring due to extensive skin lesions<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Secondary attack rates of up to 80\u201390% among non-immune individuals<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<\/ul>\n<p><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><b>Vaccination remains the most effective intervention to reduce disease incidence, prevent complications, and limit outbreaks in schools and communities.<\/b><\/span><\/p>\n<h2><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><b>7. NAVIVA GROUP \u2013 Authorized Distributor of the Second-Generation MAV\/06 Varicella Vaccine (BARYCELA inj., GC Biopharma \u2013 South Korea) in Vietnam<\/b><\/span><\/h2>\n<p><span style=\"font-weight: 400; color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">With more than 21 years of experience, NAVIVA Group is a trusted partner to healthcare facilities in the distribution of vaccines and biological products.<\/span><\/p>\n<p><span style=\"font-weight: 400; color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">NAVIVA Group\u2019s supply capabilities include:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">GDP-compliant cold chain storage and transportation systems in Hanoi, Da Nang, and Ho Chi Minh City<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">A professional, well-trained workforce<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\"><span style=\"font-weight: 400;\">Communication support and post-marketing services for partners<\/span><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400; color: #000000; font-size: 14pt; font-family: 'times new roman', times, serif;\">NAVIVA Group is committed to ensuring a stable supply of high-quality vaccines, fully compliant with Ministry of Health regulations and manufacturer guidelines.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BARYCELA inj. is a varicella vaccine manufactured by GC Biopharma (South Korea). With more than 30 years of experience and a presence in over 30 countries, GC Biopharma is recognized as one of Asia\u2019s leading and most reputable vaccine manufacturers. 1. A 30-Year Journey in Varicella Vaccine Development by GC Biopharma GC Biopharma is a [&hellip;] <\/p>\n","protected":false},"author":4,"featured_media":2427,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[25],"tags":[],"class_list":["post-2519","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts\/2519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/comments?post=2519"}],"version-history":[{"count":2,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts\/2519\/revisions"}],"predecessor-version":[{"id":2521,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/posts\/2519\/revisions\/2521"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/media\/2427"}],"wp:attachment":[{"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/media?parent=2519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/categories?post=2519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/naviva.com.vn\/en\/wp-json\/wp\/v2\/tags?post=2519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}